Board of Advisors

Gary Zweiger is a co-founder, investor, and adviser at Fluent BioSciences. He served as a venture partner and operating partner at Cota Capital from 2020 to 2022. Prior to that Gary co-founded and was managing director at BioInflexion Point Partners, a firm that helped companies in the life sciences bring innovative technologies to commercial readiness. He supported companies such as Moleculo (sold to Illumina), Zephyrus Biosciences (sold to BioTechne), Blueprint Genetics (sold to Quest Diagnostics) and Mission Bio. Gary has over 20 years of experience in business development with leadership roles at Agilent Technologies, ABI (Thermo), Affymetrix (Thermo), and Bionano. He completed his BS degree in Biological Sciences at Stanford University, obtained a PhD in Genetics from Stanford University’s School of Medicine, and completed a post-doctoral fellowship at Genentech.

Kristin brings over two decades of experience advising healthcare and life sciences organizations on strategy, market access, and commercialization. She has partnered with biopharmaceutical companies, digital health innovators, and financial sponsors to design and execute pathways that accelerate growth and maximize impact.

Kristin has held senior leadership roles, including Chief Strategy & Product Officer of a SaaS startup supporting biopharma commercialization planning and Vice President of Research at a market insights firm serving global life sciences and financial clients. As Founder of Impetus Health, she has provided strategic counsel across all stages of product development, guiding early-stage companies through market entry and enabling established organizations to scale effectively. Her expertise spans strategic planning, reimbursement, integration, and market research, with a strong track record of helping clients prepare for launches, transactions, and value creation. She holds a Master of Public Health in Health Services from Boston University and a BA in Economics from the University of New Hampshire.

Gary Yeung is a life science investor, executive, co-founder, board member and advisor with extensive experience forming and building biotech companies and developing novel therapies. He has raised over $600 million in capital and has co-founded three biotech startups and a venture capital firm: two spin-offs from Stanford University and Duke University, GGTG Biosciences and YK Bioventures Capital. Gary has also built multiple biotech companies: Xilis, NiKang, Erasca, Guardant Health and Annexon (NASDAQ: ERAS, GH and ANNX) as well as leading organizations engaged in filing 42 INDs and launching multiple FDA-approved treatments at Genentech. He is a former strategy consultant and operational leader at McKinsey and GE.

Frank is founder of Arsenal Life Science, a consulting firm he founded in 2018 and is a recognized thought leader in the life sciences and biotech industries. Frank has spent over twenty years in biopharmaceuticals serving in commercial leadership roles and leading companies through times of great transformation. At Takeda, Amylin, and Acadia Pharmaceuticals he was a founding member of the team that brought them from R&D-only into launch-ready commercial organizations. His 15 product launches include large market brands such as Lipitor to orphan drug portfolios. Frank’s strong record of increasing company value has resulted in company acquisitions of over $100 billion.